Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gilead Trial Pause Adds To Merck & Co’s HIV Concerns

Might Be End Of Partnership

Executive Summary

The partners are halting recruitment out of “an abundance of caution,” but Gilead could decide to exit the alliance if islatravir cannot shake off safety concerns.

You may also be interested in...



GSK Looks To Long-Acting Therapy To Restore Lead In HIV

GSK looks to Cabenuva to get ahead in the long-acting HIV therapy and PrEP market, but Gilead will not relinquish its lead easily.

Safety Concerns Halt Merck & Co’s Once-Weekly HIV Combination

Merck & Co. is looking to compete in the burgeoning long-acting HIV market, but a safety halt to a Phase II trial could disrupt those plans.

Merck & Co./Gilead Team To Take On ViiV In Long-Term HIV Treatment

The companies hope the combination of islatravir and lenacapavir will result in best-in-class oral and injectable long-term HIV products. A PrEP combo is a longer-term goal.

Topics

Related Companies

UsernamePublicRestriction

Register

SC145472

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel